Concord Biotech Limited (CONCORDBIO) — Capital Reinvestment Ratio
Latest as of March 2025:
0.45x
Concord Biotech Limited (CONCORDBIO) has a Capital Reinvestment Ratio of 0.45x as of March 2025, meaning it reinvests 0% of its operating cash flow (Rs2.47 Billion) in capital expenditures (Rs1.11 Billion). See CONCORDBIO FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.45x
Capex / Operating Cash Flow
Operating Cash Flow
Rs2.47 Billion
INR
Capital Expenditures
Rs1.11 Billion
INR
Data as of
Mar 2025
Most recent filing
Concord Biotech Limited Capital Reinvestment Ratio (2020–2025)
This chart tracks Concord Biotech Limited's Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for Concord Biotech Limited (2020–2025)
Year-by-year Capital Reinvestment Ratio for Concord Biotech Limited from 2020 to 2025. For live market cap and broader valuation context, see CONCORDBIO market cap overview.
| Year | Reinvestment Ratio | Operating CF (INR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.45x | Rs2.47 Billion | Rs1.11 Billion | ▲ +39.2% |
| 2024 | 0.32x | Rs2.65 Billion | Rs856.88 Million | ▼ -45.3% |
| 2023 | 0.59x | Rs2.46 Billion | Rs1.45 Billion | ▼ -21.3% |
| 2022 | 0.75x | Rs2.07 Billion | Rs1.56 Billion | ▼ -38.8% |
| 2021 | 1.22x | Rs1.67 Billion | Rs2.04 Billion | ▲ +21.9% |
| 2020 | 1.00x | Rs1.55 Billion | Rs1.55 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow